Erwin G Van Meir

List of Publications by Year in Descending Order

75 papers	9,246 citations	39 h-index	77 g-index
77 ext. papers	10,870 ext. citations	12.2 avg, IF	5.35 L-index

#	Paper	IF	Citations
75	Mice lacking full length Adgrb1 (Bai1) exhibit social deficits, increased seizure susceptibility, and altered brain development.. *Experimental Neurology*, **2022**, 351, 113994	5.7	0
74	The transcriptional landscape of Shh medulloblastoma. *Nature Communications*, **2021**, 12, 1749	17.4	7
73	Ten-eleven translocation protein 1 modulates medulloblastoma progression. *Genome Biology*, **2021**, 22, 125	18.3	0
72	Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. *Oncogene*, **2021**, 40, 5182-5191	9.2	3
71	CBMS-7 IGF1/N-cadherin/Clusterin signaling axis mediates adaptive radioresistance of glioma stem cells. *Neuro-Oncology Advances*, **2021**, 3, vi3-vi3	0.9	
70	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. *Cell Reports Medicine*, **2020**, 1,	18	11
69	A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis. *Clinical Cancer Research*, **2020**, 26, 2711-2724	12.9	4
68	The advent of precision epigenetics for medulloblastoma. *Oncoscience*, **2020**, 7, 47-48	0.8	
67	EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. *Oncogene*, **2020**, 39, 1041-1048	9.2	14
66	The expanding functional roles and signaling mechanisms of adhesion G protein-coupled receptors. *Annals of the New York Academy of Sciences*, **2019**, 1456, 5-25	6.5	7
65	A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresis. *Scientific Reports*, **2019**, 9, 4437	4.9	18
64	Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma. *Clinical Cancer Research*, **2019**, 25, 2206-2218	12.9	29
63	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. *Cancer Cell*, **2018**, 33, 1004-1016.e5	24.3	24
62	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. *Clinical Cancer Research*, **2018**, 24, 6471-6482	12.9	24
61	Cancer therapy: Neutrophils traffic in cancer nanodrugs. *Nature Nanotechnology*, **2017**, 12, 616-618	28.7	16
60	Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2017**, 31, 737-754.e6	24.3	511
59	Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. *Bio-protocol*, **2017**, 7,	0.9	1

58	A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. *Oncotarget*, **2017**, 8, 99245-99260	3.3	7
57	Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 992-1001	5.6	6
56	BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. *Clinical Cancer Research*, **2017**, 23, 1809-1819	12.9	20
55	Two new species of betatorqueviruses identified in a human melanoma that metastasized to the brain. *Oncotarget*, **2017**, 8, 105800-105808	3.3	11
54	Adhesion GPCRs in Tumorigenesis. *Handbook of Experimental Pharmacology*, **2016**, 234, 369-396	3.2	44
53	Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. *Clinical Cancer Research*, **2016**, 22, 6256-6265	12.9	28
52	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
51	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
50	A role for activated Cdc42 in glioblastoma multiforme invasion. *Oncotarget*, **2016**, 7, 56958-56975	3.3	22
49	Biology of advanced uveal melanoma and next steps for clinical therapeutics. *Pigment Cell and Melanoma Research*, **2015**, 28, 135-47	4.5	62
48	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. *Genome Research*, **2015**, 25, 316-27	9.7	240
47	Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. *Molecular Cell*, **2014**, 53, 534-48	17.6	184
46	Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. *Cancer Research*, **2014**, 74, 4536-48	10.1	68
45	SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. *Oncotarget*, **2014**, 5, 9703-9	3.3	24
44	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
43	Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. *Future Medicinal Chemistry*, **2013**, 5, 553-72	4.1	93
42	Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 interaction with cofactors p300/CBP. *Clinical Cancer Research*, **2012**, 18, 6623-33	12.9	61
41	Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. *Journal of Molecular Medicine*, **2012**, 90, 1161-1171	5.5	70

40	Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. *ACS Medicinal Chemistry Letters*, **2012**, 3, 620-5	4.3	15
39	Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 4590-7	3.4	31
38	KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. *PLoS ONE*, **2012**, 7, e44883	3.7	26
37	Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. *Journal of Medicinal Chemistry*, **2011**, 54, 8471-89	8.3	39
36	Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5528-32	2.9	32
35	At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. *Journal of Molecular Medicine*, **2011**, 89, 91-4	5.5	15
34	Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. *Journal of Molecular Medicine*, **2011**, 89, 743-52	5.5	52
33	Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. *Cancer Research*, **2011**, 71, 5859-70	10.1	49
32	Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. *Ca-A Cancer Journal for Clinicians*, **2010**, 60, 166-93	220.7	950
31	Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. *Cancer Research*, **2009**, 69, 1212-20	10.1	85
30	Identification of a novel small molecule HIF-1alpha translation inhibitor. *Clinical Cancer Research*, **2009**, 15, 6128-36	12.9	84
29	Tumor initiating cells in malignant gliomas: biology and implications for therapy. *Journal of Molecular Medicine*, **2009**, 87, 363-74	5.5	67
28	Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. *Molecular Therapy*, **2008**, 16, 599-606	11.7	38
27	Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. *Clinical Cancer Research*, **2006**, 12, 2716-29	12.9	25
26	Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. *Cancer Research*, **2006**, 66, 11991-7	10.1	68
25	Hypoxia inducible factor-1: a novel target for cancer therapy. *Anti-Cancer Drugs*, **2005**, 16, 901-9	2.4	100
24	Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. *Oncogene*, **2005**, 24, 3632-42	9.2	140
23	The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. *Neuro-Oncology*, **2005**, 7, 122-33	1	527

22	Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. *Clinical Cancer Research*, **2004**, 10, 8603-12	12.9	60
21	Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. *International Journal of Biochemistry and Cell Biology*, **2004**, 36, 1046-69	5.6	391
20	Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. *American Journal of Pathology*, **2003**, 162, 19-27	5.8	82
19	Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. *Advances in Anatomic Pathology*, **2002**, 9, 24-36	5.1	73
18	Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. *International Journal of Cancer*, **2001**, 94, 35-43	7.5	12
17	Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. *Journal of Cellular Biochemistry*, **2001**, 82, 619-33	4.7	40
16	Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. *Oncogene*, **2001**, 20, 1103-9	9.2	58
15	p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. *Oncogene*, **2000**, 19, 3816-22	9.2	120
14	Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. *Oncogene*, **1999**, 18, 1447-56	9.2	103
13	Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. *Oncogene*, **1999**, 18, 5870-8	9.2	68
12	p53 and the CNS: tumors and developmental abnormalities. *Molecular Neurobiology*, **1999**, 19, 61-77	6.2	18
11	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. *Brain Pathology*, **1999**, 9, 469-79	6	424
10	p53 and brain tumors: from gene mutations to gene therapy. *Brain Pathology*, **1998**, 8, 599-613	6	50
9	Genetic instability leads to loss of both p53 alleles in a human glioblastoma. *Oncogene*, **1998**, 16, 321-6	9.2	33
8	Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. *International Journal of Cancer*, **1998**, 76, 797-800	7.5	40
7	Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. *International Journal of Cancer*, **1998**, 79, 640-4	7.5	130
6	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses **1998**, 79, 640		3
5	New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. *Oncogene*, **1997**, 15, 997-1000	9.2	47

4	Identification of nude mice in tumorigenicity assays. *International Journal of Cancer*, **1997**, 71, 310	7.5	10
3	Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. *Journal of Neuro-Oncology*, **1995**, 26, 191-8	4.8	20
2	Cytokines and tumors of the central nervous system. *Glia*, **1995**, 15, 264-88	9	81
1	Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. *International Journal of Cancer*, **1994**, 58, 240-7	7.5	131